Home
HelpTest Code WGSEQ Gamma-Globin Full Gene Sequencing, Varies
Necessary Information
A complete patient history is strongly encouraged.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 4 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in the original tube. Do not aliquot.
Specimen Stability Information: Refrigerate 30 days(preferred)/Ambient 14 days
Specimen Type: Extracted DNA from whole blood
Container/Tube: 1.5 to 2 mL tube
Specimen Volume: Entire specimen
Collection Instructions: Label specimen as extracted DNA from blood and provide indication of volume and concentration of the DNA
Specimen Stability Information: Frozen (preferred)/Refrigerate/Ambient
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Thalassemia/Hemoglobinopathy Patient Information (T358)
3. If not ordering electronically, complete, print, and send a Benign Hematology Test Request (T755) with the specimen.
Secondary ID
62982Useful For
An adjunct in the interpretation of hemoglobin electrophoresis results
Evaluation for suspected gamma variants or nondeletional hereditary persistence of fetal hemoglobin
Assessment of unstable gamma chain variants when other tests for causes of hemolysis are unrevealing
Highlights
This test should be used as an adjunct to abnormal results detected by hemoglobin electrophoresis testing. It will assist with:
-Diagnosis of nondeletional hereditary persistence of fetal hemoglobin (HPFH)
-Identification of abnormal gamma chain variants (eg, unstable, high- or low-oxygen affinity, or M hemoglobins)
-Predicting the severity of a coinherited sickling disorder
-Evaluation of unexplained neonatal anemia, cyanosis, or hyperbilirubinemia
Special Instructions
Method Name
Polymerase Chain Reaction (PCR) Amplification/Sanger Sequence Analysis
Reporting Name
Gamma Globin Full Gene SequencingSpecimen Type
VariesSpecimen Minimum Volume
Blood: 1 mL; Extracted DNA: 50 mcL at 50 ng/mcL concentration
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Varies | ||
Reject Due To
| Gross hemolysis | OK |
| Bone marrow Paraffin-embedded tissue Frozen tissue Paraffin-embedded bone marrow aspirate clot Methanol-acetic acid (MAA)-fixed pellets Moderately to severely clotted |
Reject |
Clinical Information
Hemoglobin F (HbF) is the dominant hemoglobin at birth but is gradually replaced by adult hemoglobin (HbA) during the year after birth (normal value ≤1% of total hemoglobin after age 2 years). Increased HbF levels may continue after the neonatal period and into adulthood for various reasons. Genetic causes include deletional and nondeletional forms of hereditary persistence of fetal hemoglobin (HPFH) and delta-beta thalassemia variants. Over 100 genetic variants have been described in the gamma genes and, if detectable, the protein expression will vary over time according to the overall HbF expression. Gamma globin variants can manifest either as a quantitative (gamma thalassemia or nondeletional HPFH) or a qualitative (gamma variant) abnormality. Nondeletional HPFH alterations frequently modulate the expected severity of sickling disorders due to the inhibitory properties of HbF on sickle formation. Many gamma chain variants are benign, although some, such as unstable, high- and low-oxygen affinity, or M hemoglobin variants, cause hemolytic anemia/hyperbilirubinemia, erythrocytosis, cyanosis, and methemoglobinemia, respectively. The percentages of gamma variants will vary according to if they are present on the HBG1 or HBG2 genes, as these genes are differentially expressed depending on the age of the patient. Symptoms due to gamma variants are expected to decrease along with the normal decrease in HbF and therefore, most resolve after the first 6 months of life.
Reference Values
An interpretive report will be provided.
Interpretation
An interpretive report will be provided and will include specimen information, assay information, and whether the specimen was positive for any variants in the gene. If positive, the alteration will be correlated with clinical significance if known.
Cautions
This test cannot be used in isolation to confirm or exclude hemoglobin conditions. Large deletions, crossover events, as well as other variants may not be detected. This test is used in conjunction with adequately studied protein analysis results.
If multiple alterations are identified, gamma globin gene sequencing is not able to distinguish between variants that are found in the same allele (in cis) and variants found on different alleles (in trans). This limitation of sequencing may complicate diagnosis or classification and has implications for inheritance and genetic counseling. To resolve these cases, molecular results must be correlated with electrophoretic and protein data and/or family studies.
Clinical Reference
1. Crowley MA, Mollan TL, Abdulmalik OY, et al. A hemoglobin variant associated with neonatal cyanosis and anemia. N Engl J Med. 2011;364(19):1837-1843
2. Cui J, Baysdorfer C, Azimi M, et al. Identification of three novel Hb F variants: Hb F-Hayward [(G)gamma1(NA1)Gly>Asp, GGT>GAT], Hb F-Chori-I [(A)gammaT16(A13)Gly>Asp, GGC>GAC] and Hb F-Chori-II [(A)gammaI29(B11)Gly>Glu, GGA>GAA]. Hemoglobin. 2012;36:305-309
3. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19-27
4. Steinberg M, Forget B, Higgs D, Weatherall D, eds. Disorders of Hemoglobin Genetics, Pathophysiology, and Clinical Management. 2nd ed. Cambridge University Press; 2009
5. Provan D, Gribben J, eds. Molecular Hematology. 3rd ed. Blackwell Publishing; 2010
6. Hoyer JD, Kroft SH, eds. Color Atlas of Hemoglobin Disorders: A Compendium Based on Proficiency Testing. College of American Pathologists; 2003
7. Merchant S, Oliveira JL, Hoyer JD, Viswanatha DS. Molecular diagnosis in hematopathology. In: Goldblum J. Hsi E, eds. Hematopathology: A Volume in the Series: Foundations in Diagnostic Pathology. 2nd ed. Churchill Livingstone; 2012:chap 24
8. Semkiu KM, Oliveira JL, Nguyen PL, Porter TR, Wilson DB. Hb F-Wentzville [(G)gamma24(B6)Gly>Glu; HBG2: c.74G>A, p.Gly25Glu]: An unstable (G)gamma-globin variant associated with neonatal hemolytic anemia. Hemoglobin. 2020;44(1):67-69. doi:10.1080/03630269.2020.1716002
Method Description
Total genomic DNA is extracted from the sample, and the full gamma globin genes are amplified by polymerase chain reaction in separate reactions followed by Sanger sequencing. Review of the sequence data is performed using a combination of automated calls and manual inspection.(Unpublished Mayo method)
Day(s) Performed
Monday through Friday
Report Available
10 daysSpecimen Retention Time
Blood: 2 weeks; DNA: 3 monthsPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81479-Unlisted molecular
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| WGSEQ | Gamma Globin Full Gene Sequencing | 95795-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 46952 | Gamma Globin Gene Sequencing Result | 50397-9 |
| 46953 | Gamma Globin Interpretation | 59466-3 |